Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Status:
Recruiting
Trial end date:
2023-05-04
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well rituximab hyaluronidase and combination chemotherapy work
in treating patients in Uganda with Burkitt lymphoma, diffuse large B-cell lymphoma, or
Kaposi sarcoma herpesvirus associated multicentric Castleman disease. Rituximab hyaluronidase
is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20,
which is found on B cells (a type of white blood cell) and some types of cancer cells. This
may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by
injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is
faster than giving rituximab alone by infusion into the blood. Drugs used in chemotherapy,
such as cyclophosphamide, vincristine, methotrexate, etoposide, doxorubicin, and prednisone
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. While rituximab has a clear
survival benefit in patients within developed countries, differences in supportive care and
infectious co-morbidities require special attention. Giving rituximab hyaluronidase alone or
in combination with chemotherapy may work better in treating patients with Burkitt lymphoma,
diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated multicentric
Castleman disease compared to chemotherapy alone in Uganda.